[HTML][HTML] BET bromodomain inhibitors: novel design strategies and therapeutic applications

KKW To, E Xing, RC Larue, PK Li - Molecules, 2023 - mdpi.com
The mammalian bromodomain and extra-terminal domain (BET) family of proteins consists
of four conserved members (Brd2, Brd3, Brd4, and Brdt) that regulate numerous cancer …

[HTML][HTML] Unravelling the role of NFE2L1 in stress responses and related diseases

X Liu, C Xu, W Xiao, N Yan - Redox Biology, 2023 - Elsevier
The nuclear factor erythroid 2 (NF-E2)-related factor 1 (NFE2L1, also known as Nrf1) is a
highly conserved transcription factor that belongs to the CNC-bZIP subfamily. Its significance …

[PDF][PDF] The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells

M Oroń, M Grochowski, A Jaiswar, J Legierska… - Cell Reports, 2022 - cell.com
Proteasome machinery is a major proteostasis control system in human cells, actively
compensated upon its inhibition. To understand this compensation, we compared global …

[HTML][HTML] Recent research progress of chiral small molecular antitumor-targeted drugs approved by the FDA from 2011 to 2019

X Chu, Y Bu, X Yang - Frontiers in Oncology, 2021 - frontiersin.org
Chiral drugs usually contain chiral centers, which are present as single enantiomers or
racemates. Compared with achiral drugs, they have significant advantages in safety and …

[HTML][HTML] The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma

T Paradzik, C Bandini, E Mereu, M Labrador, E Taiana… - Cancers, 2021 - mdpi.com
Simple Summary In the last decade, proteasome inhibitors (PIs) have become a standard for
the treatment of multiple myeloma (MM). As a consequence of the pleiotropic effects of PIs …

[HTML][HTML] mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer

A Kumari, L Gesumaria, YJ Liu, VK Hughitt, X Zhang… - JCI insight, 2023 - ncbi.nlm.nih.gov
Small cell lung cancer (SCLC) is a recalcitrant malignancy with limited treatment options.
Bromodomain and extraterminal domain inhibitors (BETis) have shown promising preclinical …

Trash talk: mammalian proteasome regulation at the transcriptional level

HEK Kaya, SK Radhakrishnan - Trends in Genetics, 2021 - cell.com
The key to a healthy mammalian cell lies in properly functioning proteolytic machineries
called proteasomes. The proteasomes are multisubunit complexes that catalyze the …

[HTML][HTML] Transcription factor Nrf1 regulates proteotoxic stress-induced autophagy

MA Ward, JR Vangala, HE Kamber Kaya… - Journal of Cell …, 2024 - rupress.org
Cells exposed to proteotoxic stress invoke adaptive responses aimed at restoring
proteostasis. Our previous studies have established a firm role for the transcription factor …

[HTML][HTML] The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma

M Sellin, S Berg, P Hagen, J Zhang - Translational Oncology, 2022 - Elsevier
Multiple myeloma (MM) treatment regimens have vastly improved since the introduction of
immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies; however …

[HTML][HTML] Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma

M Li, Y Han, C Wang, W Kang, W Jiang… - Journal of Experimental …, 2022 - Springer
Background Medulloblastoma is the most common malignant pediatric brain tumor and
group 3 subtype medulloblastoma (G3-MB) exhibits the worst prognosis. Super enhancers …